Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.

Zech SG, Carr M, Mohemmad QK, Narasimhan NI, Murray C, Rozamus LW, Dalgarno DC.

J Antibiot (Tokyo). 2011 Sep;64(9):649-54. doi: 10.1038/ja.2011.61.

PMID:
21792211
2.

Use of liquid chromatography/tandem mass spectrometric molecular fingerprinting for the rapid structural identification of pharmaceutical impurities.

Li M, Wang X, Chen B, Lin M, Buevich AV, Chan TM, Rustum AM.

Rapid Commun Mass Spectrom. 2009 Nov;23(22):3533-42. doi: 10.1002/rcm.4276.

PMID:
19844969
3.

Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: application to active pharmaceutical ingredient process development.

Chen Y, Brill GM, Benz NJ, Leanna MR, Dhaon MK, Rasmussen M, Zhou CC, Bruzek JA, Bellettini JR.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):106-17.

PMID:
17826364
4.

Identification, characterization and quantification of new impurities by LC-ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient.

Thomas S, Shandilya S, Bharati A, Paul SK, Agarwal A, Mathela CS.

J Pharm Biomed Anal. 2012 Jan 5;57:39-51. doi: 10.1016/j.jpba.2011.08.014.

PMID:
21880452
5.

Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.

Thomas S, Bharti A, Maddhesia PK, Shandilya S, Agarwal A, Dharamvir, Biswas S, Bhansal V, Gupta AK, Tewari PK, Mathela CS.

J Pharm Biomed Anal. 2012 Mar 5;61:165-75. doi: 10.1016/j.jpba.2011.11.024.

PMID:
22178334
6.

Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).

Thomas S, Paul SK, Shandilya S, Agarwal A, Saxena N, Awasthi AK, Matta Hb, Vir D, Mathela CS.

Analyst. 2012 Aug 7;137(15):3571-82. doi: 10.1039/c2an35454c.

PMID:
22733388
7.

Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.

Freed AL, Kale U, Ando H, Rossi DT, Kingsmill CA.

J Pharm Biomed Anal. 2004 Jun 29;35(4):727-38.

PMID:
15193717
8.
9.
10.

The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.

Pan C, Liu F, Ji Q, Wang W, Drinkwater D, Vivilecchia R.

J Pharm Biomed Anal. 2006 Feb 24;40(3):581-90.

PMID:
16242883
12.

Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.

Raj TJ, Bharati CH, Rao KR, Rao PS, Narayan GK, Parikh K.

J Pharm Biomed Anal. 2007 Mar 12;43(4):1470-5.

PMID:
17125952
13.

NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.

Háda V, Dubrovay Z, Lakó-Futó A, Galambos J, Gulyás Z, Aranyi A, Szántay C Jr.

J Pharm Biomed Anal. 2013 Oct;84:309-22. doi: 10.1016/j.jpba.2012.09.008.

PMID:
23177164
14.

Comparison of impurity profiles of Orlistat pharmaceutical products using HPLC tandem mass spectrometry.

Schneider A, Wessjohann LA.

J Pharm Biomed Anal. 2010 Nov 2;53(3):767-72. doi: 10.1016/j.jpba.2010.05.010.

PMID:
20570457
15.

Structural identification and characterization of impurities in ceftizoxime sodium.

Bharathi Ch, Prasad ChS, Bharathi DV, Shankar R, Rao VJ, Dandala R, Naidu A.

J Pharm Biomed Anal. 2007 Jan 17;43(2):733-40.

PMID:
16950586
16.

Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus.

Boernsen KO, Egge-Jacobsen W, Inverardi B, Strom T, Streit F, Schiebel HM, Benet LZ, Christians U.

J Mass Spectrom. 2007 Jun;42(6):793-802.

PMID:
17511017
17.

[Analysis and evaluation of the impurity of felodipine and its tablets].

Zhang N, Yu LJ, Li J, Tong JW, Meng J, Zhang QM, Shi YQ.

Yao Xue Xue Bao. 2012 Feb;47(2):223-8. Chinese.

PMID:
22512035
18.

Semi-preparative isolation and structural elucidation of an impurity in citalopram by LC/MS/MS.

Raman B, Sharma BA, Ghugare PD, Karmuse PP, Kumar A.

J Pharm Biomed Anal. 2009 Oct 15;50(3):377-83. doi: 10.1016/j.jpba.2009.05.017.

PMID:
19556091
19.

Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.

Chen Q, Zielinski D, Chen J, Nowak S, Zhou CC.

J Pharm Biomed Anal. 2009 Dec 5;50(5):778-86. doi: 10.1016/j.jpba.2009.06.024.

PMID:
19581067
20.

Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.

Bharathi Ch, Jayaram P, Sunder Raj J, Saravana Kumar M, Bhargavi V, Handa VK, Dandala R, Naidu A.

J Pharm Biomed Anal. 2008 Dec 1;48(4):1211-8. doi: 10.1016/j.jpba.2008.08.011.

PMID:
18947955
Items per page

Supplemental Content

Support Center